J Charles Jennette

List of Publications by Year in Descending Order

182 papers	23,525 citations	65 h-index	153 g-index
191 ext. papers	27,167 ext. citations	8.8 avg, IF	6.59 L-index

#	Paper	IF	Citations
182	Fabry Disease Associated With Antiglomerular Basement Membrane Disease: Chance or Consequence.. *Kidney International Reports*, **2022**, 7, 658-659	4.1	
181	Impact of Consensus Definitions on Identification of Glomerular Lesions by Light and Electron Microscopy.. *Kidney International Reports*, **2022**, 7, 78-86	4.1	0
180	Mechanisms of vascular damage in ANCA vasculitis.. *Seminars in Immunopathology*, **2022**, 1	12	1
179	Cyanocobalamin prevents cardiomyopathy in type 1 diabetes by modulating oxidative stress and DNMT-SOCS1/3-IGF-1 signaling. *Communications Biology*, **2021**, 4, 775	6.7	1
178	Kinin B1 Receptor Is Important in the Pathogenesis of Myeloperoxidase-Specific ANCA GN. *Journal of the American Society of Nephrology: JASN*, **2020**, 31, 297-307	12.7	7
177	Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis. *Kidney International Reports*, **2020**, 5, 1228-1239	4.1	3
176	ANCA autoantigen gene expression highlights neutrophil heterogeneity where expression in normal-density neutrophils correlates with ANCA-induced activation. *Kidney International*, **2020**, 98, 744-757	9.8	5
175	Introduction: Nomenclature and Classification. *Rare Diseases of the Immune System*, **2020**, 3-17	0.2	
174	Necrotizing Arteritis and Small-Vessel Vasculitis **2020**, 1285-1311		1
173	Content and Performance of the MiniMUGA Genotyping Array: A New Tool To Improve Rigor and Reproducibility in Mouse Research. *Genetics*, **2020**, 216, 905-930	4	17
172	2020 international consensus on ANCA testing beyond systemic vasculitis. *Autoimmunity Reviews*, **2020**, 19, 102618	13.6	36
171	Consensus definitions for glomerular lesions by light and electron microscopy: recommendations from a working group of the Renal Pathology Society. *Kidney International*, **2020**, 98, 1120-1134	9.9	15
170	Restricted myeloperoxidase epitopes drive the adaptive immune response in MPO-ANCA vasculitis. *Journal of Autoimmunity*, **2020**, 106, 102306	15.5	11
169	Overcoming anti-PEG antibody mediated accelerated blood clearance of PEGylated liposomes by pre-infusion with high molecular weight free PEG. *Journal of Controlled Release*, **2019**, 311-312, 138-146	11.7	29
168	Elevated Microparticle Tissue Factor Activity Differentiates Patients With Venous Thromboembolism in Anti-neutrophil Cytoplasmic Autoantibody Vasculitis. *Kidney International Reports*, **2019**, 4, 1617-1629	4.1	10
167	Measuring Circulating Complement Activation Products in Myeloperoxidase- and Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. *Arthritis and Rheumatology*, **2019**, 71, 1894-1903	9.5	19
166	Immunoglobulins G from patients with ANCA-associated vasculitis are atypically glycosylated in both the Fc and Fab regions and the relation to disease activity. *PLoS ONE*, **2019**, 14, e0213215	3.7	17

165	Understanding Long-term Remission Off‐Therapy in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. *Kidney International Reports*, **2019**, 4, 551-560	4.1	6
164	Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study. *Genetics in Medicine*, **2019**, 21, 1987-1997	8.1	34
163	A renal risk score for ANCA-associated glomerulonephritis. *Kidney International*, **2019**, 96, 245	9.9	3
162	Engulfment and cell motility protein 1 potentiates diabetic cardiomyopathy via Rac-dependent and Rac-independent ROS production. *JCI Insight*, **2019**, 4,	9.9	8
161	Histopathology of Glomerular Diseases **2019**, 43-58		
160	CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. *American Journal of Kidney Diseases*, **2019**, 73, 218-229	7.4	39
159	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney International*, **2019**, 95, 268-280	9.9	145
158	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney International*, **2019**, 95, 281-295	9.9	87
157	Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. *Kidney International*, **2018**, 93, 789-796	9.9	234
156	Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey. *Nephrology Dialysis Transplantation*, **2018**, 33, 661-669	4.3	63
155	Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial. *Orphanet Journal of Rare Diseases*, **2018**, 13, 68	4.2	16
154	Predicting Outcome in Patients with Anti-GBM Glomerulonephritis. *Clinical Journal of the American Society of Nephrology: CJASN*, **2018**, 13, 63-72	6.9	33
153	Histopathology of Glomerular Diseases **2018**, 1-16		
152	Segmental Sclerosis and Extracapillary Hypercellularity Predict Diabetic ESRD. *Journal of the American Society of Nephrology: JASN*, **2018**, 29, 694-703	12.7	30
151	Pathogenesis of ANCA-Associated Pulmonary Vasculitis. *Seminars in Respiratory and Critical Care Medicine*, **2018**, 39, 413-424	3.9	20
150	Glomerulonephritis in Animal Models and Human Medicine: Discovery, Pathogenesis, and Diagnostics. *Toxicologic Pathology*, **2018**, 46, 898-903	2.1	2
149	Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. *Kidney International Reports*, **2018**, 3, 1373-1384	4.1	23
148	Eosinophilic Granulomatosis with Polyangiitis: Clinical Pathology Conference and Review. *Journal of Allergy and Clinical Immunology: in Practice*, **2018**, 6, 1496-1504	5.4	26

147	Interstital lung disease in ANCA vasculitis. *Autoimmunity Reviews*, **2017**, 16, 722-729	13.6	78
146	Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy. *Kidney International*, **2017**, 91, 235-243	9.9	42
145	Temporal and Demographic Trends in Glomerular Disease Epidemiology in the Southeastern United States, 1986-2015. *Clinical Journal of the American Society of Nephrology: CJASN*, **2017**, 12, 614-623	6.9	69
144	ANCA Glomerulonephritis and Vasculitis. *Clinical Journal of the American Society of Nephrology: CJASN*, **2017**, 12, 1680-1691	6.9	155
143	Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. *Nature Reviews Rheumatology*, **2017**, 13, 683-692	8.1	183
142	Gene-Specific DNA Methylation Changes Predict Remission in Patients with ANCA-Associated Vasculitis. *Journal of the American Society of Nephrology: JASN*, **2017**, 28, 1175-1187	12.7	27
141	Nicotinamide benefits both mothers and pups in two contrasting mouse models of preeclampsia. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 13450-13455	11.5	34
140	Renal Survival in Patients with Collapsing Compared with Not Otherwise Specified FSGS. *Clinical Journal of the American Society of Nephrology: CJASN*, **2016**, 11, 1752-1759	6.9	29
139	Nomenclature of Vasculitides: 2012 Revised International Chapel Hill Consensus Conference **2016**, 15-28		12
138	Histone modification signature at myeloperoxidase and proteinase 3 in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis. *Clinical Epigenetics*, **2016**, 8, 85	7.7	15
137	Overview of the Pathogenesis of ANCA-Associated Vasculitis. *Kidney Diseases (Basel, Switzerland)*, **2016**, 1, 205-15	3.3	65
136	Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS. *Clinical Journal of the American Society of Nephrology: CJASN*, **2016**, 11, 386-94	6.9	36
135	High Elmo1 expression aggravates and low Elmo1 expression prevents diabetic nephropathy. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 2218-22	11.5	30
134	Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN. *Journal of the American Society of Nephrology: JASN*, **2016**, 27, 1278-87	12.7	132
133	Dysregulation of autoantigen genes in ANCA-associated vasculitis involves alternative transcripts and new protein synthesis. *Journal of the American Society of Nephrology: JASN*, **2015**, 26, 390-9	12.7	18
132	Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy. *American Journal of Kidney Diseases*, **2015**, 66, 783-91	7.4	55
131	Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. *European Journal of Internal Medicine*, **2015**, 26, 545-53	3.9	254
130	Low TGF1 expression prevents and high expression exacerbates diabetic nephropathy in mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 5815-20	11.5	49

129	Palladin is upregulated in kidney disease and contributes to epithelial cell migration after injury. *Scientific Reports*, **2015**, 5, 7695	4.9	7
128	Autoimmunity to the alpha 3 chain of type IV collagen in glomerulonephritis is triggered by 'autoantigen complementarity'. *Journal of Autoimmunity*, **2015**, 59, 8-18	15.5	9
127	Glomerular Clinicopathologic Syndromes **2014**, 152-163		2
126	Necrotizing Arteritis and Small Vessel Vasculitis **2014**, 1067-1086		
125	B cell-mediated pathogenesis of ANCA-mediated vasculitis. *Seminars in Immunopathology*, **2014**, 36, 327-38	12	27
124	Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure. *Clinical Journal of the American Society of Nephrology: CJASN*, **2014**, 9, 905-13	6.9	84
123	Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. *Nature Reviews Rheumatology*, **2014**, 10, 463-73	8.1	275
122	Diseases of Medium-Sized and Small Vessels **2014**, 197-219		6
121	Rare hereditary COL4A3/COL4A4 variants may be mistaken for familial focal segmental glomerulosclerosis. *Kidney International*, **2014**, 86, 1253-9	9.9	156
120	Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy. *Kidney International*, **2014**, 85, 1412-20	9.9	55
119	IgA Nephropathy and IgA Vasculitis (Henoch-Schönlein Purpura) **2014**, 69-78		1
118	Fundamentals of Renal Pathology **2014**,		5
117	C5a receptor (CD88) blockade protects against MPO-ANCA GN. *Journal of the American Society of Nephrology: JASN*, **2014**, 25, 225-31	12.7	181
116	Allograft Rejection **2014**, 197-216		
115	Crescentic Glomerulonephritis and Vasculitis **2014**, 107-122		
114	Lupus Nephritis **2014**, 89-105		
113	Minimal Change Disease and Focal Segmental Glomerulosclerosis **2014**, 45-58		
112	Complement in ANCA-associated vasculitis. *Seminars in Nephrology*, **2013**, 33, 557-64	4.8	37

111	L1. Pathogenesis of ANCA-associated vasculitis: observations, theories and speculations. *Presse Medicale*, **2013**, 42, 493-8	2.2	13
110	L17. What can we expect from the revised Chapel Hill consensus conference nomenclature of vasculitis?. *Presse Medicale*, **2013**, 42, 550-5	2.2	4
109	Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. *Clinical and Experimental Nephrology*, **2013**, 17, 603-606	2.5	242
108	Genetically determined severity of anti-myeloperoxidase glomerulonephritis. *American Journal of Pathology*, **2013**, 182, 1219-26	5.8	19
107	Immunologic Mechanisms of Vasculitis **2013**, 2817-2846		2
106	Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. *Annual Review of Pathology: Mechanisms of Disease*, **2013**, 8, 139-60	34	178
105	Association of histologic variants in FSGS clinical trial with presenting features and outcomes. *Clinical Journal of the American Society of Nephrology: CJASN*, **2013**, 8, 399-406	6.9	93
104	Digital pathology evaluation in the multicenter Nephrotic Syndrome Study Network (NEPTUNE). *Clinical Journal of the American Society of Nephrology: CJASN*, **2013**, 8, 1449-59	6.9	55
103	Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. *Journal of Clinical Investigation*, **2013**, 123, 1773-83	15.9	165
102	A position paper on standardizing the nonneoplastic kidney biopsy report. *Human Pathology*, **2012**, 43, 1192-6	3.7	12
101	Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. *Arthritis and Rheumatism*, **2012**, 64, 3452-62		256
100	High basal activity of the PTPN22 gain-of-function variant blunts leukocyte responsiveness negatively affecting IL-10 production in ANCA vasculitis. *PLoS ONE*, **2012**, 7, e42783	3.7	29
99	Novel quantitative method to evaluate globotriaosylceramide inclusions in renal peritubular capillaries by virtual microscopy in patients with fabry disease. *Archives of Pathology and Laboratory Medicine*, **2012**, 136, 816-24	5	22
98	A position paper on standardizing the nonneoplastic kidney biopsy report. *Clinical Journal of the American Society of Nephrology: CJASN*, **2012**, 7, 1365-8	6.9	17
97	Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis. *Journal of the American Society of Nephrology: JASN*, **2012**, 23, 545-55	12.7	99
96	Pathogenesis of antineutrophil cytoplasmic autoantibody vasculitis. *Current Opinion in Nephrology and Hypertension*, **2011**, 20, 263-70	3.5	87
95	DRB1*15 allele is a risk factor for PR3-ANCA disease in African Americans. *Journal of the American Society of Nephrology: JASN*, **2011**, 22, 1161-7	12.7	84
94	Experimental models of vasculitis and glomerulonephritis induced by antineutrophil cytoplasmic autoantibodies. *Contributions To Nephrology*, **2011**, 169, 211-220	1.6	45

93	ANCA disease: where is this field heading?. *Journal of the American Society of Nephrology: JASN*, **2010**, 21, 745-52	12.7	98
92	Rituximab in ANCA-associated disease. *New England Journal of Medicine*, **2010**, 363, 285-6	59.2	26
91	Renal and Systemic Vasculitis **2010**, 292-307		1
90	Histopathologic classification of ANCA-associated glomerulonephritis. *Journal of the American Society of Nephrology: JASN*, **2010**, 21, 1628-36	12.7	492
89	The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. *Kidney International*, **2010**, 77, 921-7	9.9	145
88	The rise and fall of horror autotoxicus and forbidden clones. *Kidney International*, **2010**, 78, 533-5	9.9	13
87	Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. *Journal of Clinical Investigation*, **2010**, 120, 3209-19	15.9	143
86	The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. *Kidney International*, **2009**, 76, 546-56	9.9	689
85	The clinical course of ANCA small-vessel vasculitis on chronic dialysis. *Kidney International*, **2009**, 76, 644-51	9.9	77
84	C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 289-98	12.7	272
83	The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. *Kidney International*, **2009**, 76, 534-45	9.9	788
82	Kidney Involvement in Systemic Vasculitis **2009**, 200-207		
81	Glomerular Clinicopathologic Syndromes **2009**, 148-159		3
80	ISOLATION AND CHARACTERIZATION OF BIORESPONSIVE RENAL CELLS FROM HUMAN AND LARGE MAMMAL WITH CHRONIC RENAL FAILURE. *FASEB Journal*, **2009**, 23, LB143	0.9	1
79	How can the safety and diagnostic yield of percutaneous renal biopsies be optimized?. *Nature Clinical Practice Nephrology*, **2008**, 4, 126-7		1
78	New insight into the pathogenesis of vasculitis associated with antineutrophil cytoplasmic autoantibodies. *Current Opinion in Rheumatology*, **2008**, 20, 55-60	5.3	65
77	Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. *Arthritis and Rheumatism*, **2008**, 58, 2908-18		180
76	Immunologic Mechanisms of Vasculitis **2008**, 2315-2338		

75	Association of silica exposure with anti-neutrophil cytoplasmic autoantibody small-vessel vasculitis: a population-based, case-control study. *Clinical Journal of the American Society of Nephrology: CJASN*, **2007**, 2, 290-9	6.9	88
74	Anti-neutrophil cytoplasmic (ANCA) and anti-glomerular basement membrane (GBM) autoantibodies in necrotizing and crescentic glomerulonephritis. *Seminars in Immunopathology*, **2007**, 29, 459-74	12	38
73	Kawasaki Disease Arteritis and Polyarteritis Nodosa **2007**, 12, 193-199		5
72	Pathologic Classification of Vasculitis **2007**, 12, 179-185		5
71	Nosology of primary vasculitis. *Current Opinion in Rheumatology*, **2007**, 19, 10-6	5.3	59
70	ANCA Vasculitis **2007**, 12, 200-204		6
69	Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. *American Journal of Pathology*, **2007**, 170, 52-64	5.8	378
68	Myeloperoxidase interacts with endothelial cell-surface cytokeratin 1 and modulates bradykinin production by the plasma Kallikrein-Kinin system. *American Journal of Pathology*, **2007**, 171, 349-60	5.8	45
67	Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies. *Journal of the American Society of Nephrology: JASN*, **2006**, 17, 3355-64	12.7	93
66	Necrotizing Arteritis and Small Vessel Vasculitis **2006**, 899-920		
65	Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. *Journal of the American Society of Nephrology: JASN*, **2006**, 17, 1235-42	12.7	158
64	Immunoglobulin A Nephropathy and Henoch-Schönlein Purpura **2006**, 61-69		1
63	Crescentic Glomerulonephritis and Vasculitis **2006**, 99-114		
62	The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. *American Journal of Pathology*, **2005**, 167, 39-45	5.8	257
61	Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. *American Journal of Pathology*, **2005**, 167, 47-58	5.8	197
60	Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. *Annals of Internal Medicine*, **2005**, 143, 621-31	8	300
59	Autoantigen complementarity: a new theory implicating complementary proteins as initiators of autoimmune disease. *Journal of Molecular Medicine*, **2005**, 83, 12-25	5.5	43
58	A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. *Nephrology Dialysis Transplantation*, **2005**, 20, 2725-32	4.3	86

57	Pathogenesis of pulmonary vasculitis. *Seminars in Respiratory and Critical Care Medicine*, **2004**, 25, 465-74	3.9	12
56	Circumvention of normal constraints on granule protein gene expression in peripheral blood neutrophils and monocytes of patients with antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. *Journal of the American Society of Nephrology: JASN*, **2004**, 15, 2103-14	12.7	71
55	The classification of glomerulonephritis in systemic lupus erythematosus revisited. *Kidney International*, **2004**, 65, 521-30	9.9	952
54	Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. *Nature Medicine*, **2004**, 10, 72-9	50.5	283
53	The classification of glomerulonephritis in systemic lupus erythematosus revisited. *Journal of the American Society of Nephrology: JASN*, **2004**, 15, 241-50	12.7	1355
52	Rapidly progressive crescentic glomerulonephritis. *Kidney International*, **2003**, 63, 1164-77	9.9	276
51	Addendum to the International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies. *American Journal of Clinical Pathology*, **2003**, 120, 312-318	1.9	140
50	Monitoring proteinase 3 antineutrophil cytoplasmic antibodies for detection of relapses in small vessel vasculitis. *Vaccine Journal*, **2003**, 10, 769-74		24
49	Expression profile of leukocyte genes activated by anti-neutrophil cytoplasmic autoantibodies (ANCA). *Kidney International*, **2002**, 62, 1638-49	9.9	43
48	Microarray studies of gene expression in circulating leukocytes in kidney diseases. *Nephron Experimental Nephrology*, **2002**, 10, 139-49		40
47	Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. *Journal of Clinical Investigation*, **2002**, 110, 955-963	15.9	702
46	Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. *Journal of Clinical Investigation*, **2002**, 110, 955-63	15.9	334
45	ANCA are pathogenic--oh yes they are!. *Journal of the American Society of Nephrology: JASN*, **2002**, 13, 1977-1979	12.7	68
44	Implications for pathogenesis of patterns of injury in small- and medium-sized-vessel vasculitis. *Cleveland Clinic Journal of Medicine*, **2002**, 69 Suppl 2, SII33-8	2.8	25
43	Vascular Immunobiology and Immunopathology **2002**, 354-365		
42	Internalization of proteinase 3 is concomitant with endothelial cell apoptosis and internalization of myeloperoxidase with generation of intracellular oxidants. *American Journal of Pathology*, **2001**, 158, 581-92	5.8	97
41	Silica exposure in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and lupus nephritis. *Journal of the American Society of Nephrology: JASN*, **2001**, 12, 134-142	12.7	127
40	Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features. *Kidney International*, **2000**, 57, 846-62	9.9	152

39	Do vasculitis categorization systems really matter?. *Current Rheumatology Reports*, **2000**, 2, 430-8	4.9	24
38	Restriction in V kappa gene use and antigen selection in anti-myeloperoxidase response in mice. *Journal of Immunology*, **2000**, 165, 3890-7	5.3	8
37	International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). *American Journal of Clinical Pathology*, **1999**, 111, 507-13	1.9	466
36	Diagnostic usefulness of antineutrophil cytoplasmic autoantibody serology. Comparative evaluation of commercial indirect fluorescent antibody kits and enzyme immunoassay kits. *American Journal of Clinical Pathology*, **1999**, 111, 363-9	1.9	46
35	Anti-neutrophil cytoplasmic antibody (ANCA) target antigens, disease associations, and laboratory testing. *Clinical Immunology Newsletter*, **1998**, 18, 10-15		
34	Angiotensin-converting enzyme gene mutations, blood pressures, and cardiovascular homeostasis. *Hypertension*, **1997**, 29, 150-7	8.5	128
33	Small-vessel vasculitis. *New England Journal of Medicine*, **1997**, 337, 1512-23	59.2	1066
32	Are ANCA pathogenetic? Pros and cons. *Nephrology*, **1997**, 3, s780-s782	2.2	
31	The spectrum of ANCA-associated small vessel vasculitis and glomerulonephritis. *Nephrology*, **1997**, 3, s767-s769	2.2	
30	What causes ANCA?. *Nephrology*, **1997**, 3, s772-s773	2.2	
29	Antimyeloperoxidase antibodies induce neutrophil adherence to cultured human endothelial cells. *Renal Failure*, **1995**, 17, 125-33	2.9	33
28	Male-female differences in fertility and blood pressure in ACE-deficient mice. *Nature*, **1995**, 375, 146-8	50.4	566
27	The pathologic spectrum of pulmonary lesions in patients with anti-neutrophil cytoplasmic autoantibodies specific for anti-proteinase 3 and anti-myeloperoxidase. *American Journal of Clinical Pathology*, **1995**, 104, 7-16	1.9	109
26	Nomenclature of systemic vasculitides. Proposal of an international consensus conference. *Arthritis and Rheumatism*, **1994**, 37, 187-92		3044
25	Collapsing glomerulopathy: a clinically and pathologically distinct variant of focal segmental glomerulosclerosis. *Kidney International*, **1994**, 45, 1416-24	9.9	215
24	International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. *Kidney International*, **1993**, 44, 411-22	9.9	1081
23	DO ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES CAUSE WEGENER'S GRANULOMATOSIS AND OTHER FORMS OF NECROTIZING VASCULITIS?. *Rheumatic Disease Clinics of North America*, **1993**, 19, 1-14	2.4	21
22	A nephrological view of the classification of vasculitis. *Advances in Experimental Medicine and Biology*, **1993**, 336, 197-208	3.6	5

21	Acute renal failure secondary to leukocyte-mediated acute glomerular injury. *Renal Failure*, **1992**, 14, 395-9	2.9	4
20	Reactivity of antineutrophil cytoplasmic autoantibodies with mononuclear phagocytes. *Journal of Leukocyte Biology*, **1992**, 51, 65-8	6.5	59
19	Nephropathology consultation via digitized images. *Annals of the New York Academy of Sciences*, **1992**, 670, 281-92	6.5	8
18	Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. *Kidney International*, **1992**, 41, 375-83	9.9	185
17	Autoimmune Vasculitis **1992**, 279-302		2
16	Antibodies against granule proteins activate neutrophils in vitro. *Journal of Leukocyte Biology*, **1991**, 50, 539-46	6.5	174
15	Characterization of the changes in matrix molecules at the dermoepidermal junction in lupus erythematosus. *Journal of Cutaneous Pathology*, **1991**, 18, 417-22	1.7	6
14	The Third International Workshop on Antineutrophil Cytoplasmic Autoantibodies. *American Journal of Kidney Diseases*, **1991**, 18, 145-147	7.4	3
13	Antineutrophil cytoplasmic autoantibody-associated diseases: a pathologist's perspective. *American Journal of Kidney Diseases*, **1991**, 18, 164-70	7.4	84
12	Antineutrophil cytoplasmic autoantibodies: disease associations, molecular biology, and pathophysiology. *International Review of Experimental Pathology*, **1991**, 32, 193-221		26
11	Diagnosis and management of glomerulonephritis and vasculitis presenting as acute renal failure. *Medical Clinics of North America*, **1990**, 74, 893-908	7	15
10	Antineutrophil cytoplasmic autoantibodies and associated diseases: a review. *American Journal of Kidney Diseases*, **1990**, 15, 517-29	7.4	251
9	Microradiographic demonstration of human intrarenal microlymphatic pathways. *Urologic Radiology*, **1989**, 11, 83-7		19
8	Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. *New England Journal of Medicine*, **1988**, 318, 1651-7	59.2	1191
7	Overlapping IgA and membranous nephropathy. *American Journal of Clinical Pathology*, **1987**, 88, 74-8	1.9	17
6	The epithelial antigen phenotype of glomerular crescent cells. *American Journal of Clinical Pathology*, **1986**, 86, 274-80	1.9	22
5	A genetically determined murine model of infantile polycystic kidney disease. *Journal of Urology*, **1985**, 134, 828-33	2.5	60
4	Concurrent antiglomerular basement membrane antibody and immune complex mediated glomerulonephritis. *American Journal of Clinical Pathology*, **1982**, 78, 381-6	1.9	17

3	Diffuse T-cell lymphoma preceded by nodular lymphoma. *American Journal of Clinical Pathology*, **1982**, 78, 242-8	1.9	19
2	Rosette formation between chronic t-lymphocytic leukemia cells and macrophages: a facsimile of normal T-lymphocyte-macrophage cooperation. *American Journal of Hematology*, **1982**, 12, 301-4	7.1	1
1	IgA nephropathy associated with seronegative spondylarthropathies. *Arthritis and Rheumatism*, **1982**, 25, 144-9		74